Pharmacotherapy of alcohol use disorders: seventy-five years of progress
about
Guidelines for the Reporting of Treatment Trials for Alcohol Use DisordersBehavioral and Genetic Evidence for GIRK Channels in the CNS: Role in Physiology, Pathophysiology, and Drug AddictionRecommendations for the Design and Analysis of Treatment Trials for Alcohol Use DisordersUse of pharmacotherapies in the treatment of alcohol use disorders and opioid dependence in primary carePharmacotherapy for Alcohol Use Disorders: Physicians' Perceptions and PracticesThe pharmacogenetics of alcohol use disorderUnderstanding the addiction cycle: a complex biology with distinct contributions of genotype vs. sex at each stage.Tigecycline Reduces Ethanol Intake in Dependent and Nondependent Male and Female C57BL/6J Mice.A novel method for analyzing extremely biased agonism at G protein-coupled receptors.Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders.Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications DevelopmentEpidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.Genes and Alcohol Consumption: Studies with Mutant Mice.Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions.Disparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.Neurobiology of comorbid post-traumatic stress disorder and alcohol-use disorder.AAV Gene Therapy for Alcoholism: Inhibition of Mitochondrial Aldehyde Dehydrogenase Enzyme Expression in Hepatoma Cells.Effective Reduction in High Ethanol Drinking by Semisynthetic Tetracycline Derivatives.Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article.Diazepam Concurrently Increases the Frequency and Decreases the Amplitude of Transient Dopamine Release Events in the Nucleus Accumbens.Ketamine Differentially Attenuates Alcohol Intake in Male Versus Female Alcohol Preferring (P) Rats.Nicotine-Use/Smoking Is Associated with the Efficacy of Naltrexone in the Treatment of Alcohol Dependence.Effects of LY466195, a selective kainate receptor antagonist, on ethanol preference and drinking in rats.Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models.Acupuncture for alcohol use disorder.Critical Role for Gi/o-Protein Activity in the Dorsal Striatum in the Reduction of Voluntary Alcohol Intake in C57Bl/6 Mice.Disulfiram-like Reaction Involving Ceftriaxone in a Pediatric Patient.Brain Functional Magnetic Resonance Imaging Cue-reactivity Can Predict Baclofen Response in Alcohol Use DisordersPET imaging reveals lower kappa opioid receptor availability in alcoholics but no effect of age
P2860
Q26779440-9FFB5445-156B-4AB4-8966-FE6B6BD8ED95Q26783948-1C748DE6-73D7-4803-ADFB-D4E537B695AAQ27013929-EAF91DF7-B623-4C70-8AB0-8DD4B843EAA2Q28081029-2D6522F3-E83A-42CB-90F5-3097F15CFC51Q30275340-31DB7539-622B-4816-B150-42BE10BDC39FQ34463974-9FD762F8-7FBB-4B92-A932-3AE3442B7DA3Q34474335-892E3C9D-8997-4E4C-AFF0-74904B0A5EA2Q34679845-CF5AE9FB-A379-4B44-B562-D4A8A47AD1F1Q35531857-EF292DF2-F7F2-4D65-820D-1513C5E87496Q36372867-D98286F8-5FE0-4F36-9EC3-4EB341C323F0Q36936258-E908CCD4-8511-4547-9B8C-267F6CA234DDQ37059221-986D7BDD-3078-485A-8A40-33A59CC13E91Q37589721-1A565DCB-5D1F-40C1-861F-D77B2691C398Q37635751-BB7CDD15-C89D-446B-882D-68E6256D01E8Q38632136-9773064C-ABA1-4CB5-9A8A-DED042C41559Q38838575-F9EEEA0B-0494-45E4-B42B-7C8361918029Q38982604-1A83A9EA-F191-4E46-BD5F-51BB4C3501CCQ40173850-7B95BAB2-FE2B-4E6C-B6AD-5CA2446A7DD5Q45818665-8E984981-E4A9-4035-A941-799A5123AADDQ47732515-D4ADAC84-8661-4AB4-AF68-E75EBF2AB849Q48008859-E3EFB3ED-39F5-4318-A7C3-189325012DB0Q49299731-7883CEF0-12C5-46B6-9566-3A7D05E78207Q50065382-433C3FDC-6939-4E20-8DD3-937FFB0E8D91Q50356650-620572FB-A998-45DD-80DD-032779B1309AQ51084128-D4C920B0-BCCE-45AC-885E-1C9679C85D9FQ52624385-85C59235-B42D-4E65-906C-EA342C9BE3ADQ53281321-2E5C4B6D-CB50-4898-B351-D6253BCD57C1Q54957282-7D8B2BE7-DB60-473E-B861-D8CD92904E01Q56232885-B7336D29-943D-46FF-9403-7C928F00BEF3Q58692009-5C022B6E-AB06-48F7-B59B-1D46E6B0F5B4
P2860
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@ast
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@en
type
label
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@ast
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@en
prefLabel
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@ast
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@en
P2860
P1476
Pharmacotherapy of alcohol use disorders: seventy-five years of progress
@en
P2093
Henry R Kranzler
Leah R Zindel
P2860
P478
75 Suppl 17
P577
2014-01-01T00:00:00Z